Tempus to Acquire Personalis, Integrating MRD Into AI Oncology Platform
PSNL has more than doubled off its 52-week low of $3.84 on elevated volume (1.9× avg).
Summary
Tempus is acquiring Personalis for $1.5 billion, bringing its molecular residual disease (MRD) test directly into Tempus's AI-driven precision oncology platform. This is a transformative deal for Personalis, which has been burning cash and recently filed for a $150M ATM offering. The acquisition provides an exit for shareholders and validates the clinical utility of NeXT Personal. For Tempus, it adds a key diagnostic capability to its growing oncology data and AI ecosystem. The deal follows a series of Medicare coverage expansions for Personalis's test, but also a 25% revenue decline and widening losses in Q1 2026.
At the time of this announcement, PSNL was trading at $15.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.84 to $16.39. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.